- Home
- PBYI vs ENX Comparison
PBYI vs ENX Comparison
Compare PBYI & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- ENX
- Stock Information
- Founded
- PBYI 2010
- ENX 2002
- Country
- PBYI United States
- ENX United States
- Employees
- PBYI N/A
- ENX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- ENX Finance/Investors Services
- Sector
- PBYI Health Care
- ENX Finance
- Exchange
- PBYI Nasdaq
- ENX Nasdaq
- Market Cap
- PBYI 167.3M
- ENX 165.4M
- IPO Year
- PBYI N/A
- ENX N/A
- Fundamental
- Price
- PBYI $3.24
- ENX $9.21
- Analyst Decision
- PBYI Strong Buy
- ENX
- Analyst Count
- PBYI 1
- ENX 0
- Target Price
- PBYI $7.00
- ENX N/A
- AVG Volume (30 Days)
- PBYI 347.1K
- ENX 25.4K
- Earning Date
- PBYI 07-31-2025
- ENX 01-01-0001
- Dividend Yield
- PBYI N/A
- ENX 3.94%
- EPS Growth
- PBYI 143.51
- ENX N/A
- EPS
- PBYI 0.77
- ENX 0.16
- Revenue
- PBYI $232,709,000.00
- ENX N/A
- Revenue This Year
- PBYI N/A
- ENX N/A
- Revenue Next Year
- PBYI N/A
- ENX N/A
- P/E Ratio
- PBYI $4.40
- ENX $61.00
- Revenue Growth
- PBYI 2.68
- ENX N/A
- 52 Week Low
- PBYI $2.23
- ENX $7.84
- 52 Week High
- PBYI $4.13
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- PBYI 50.17
- ENX 44.79
- Support Level
- PBYI $3.38
- ENX $9.13
- Resistance Level
- PBYI $3.70
- ENX $9.24
- Average True Range (ATR)
- PBYI 0.18
- ENX 0.07
- MACD
- PBYI -0.03
- ENX 0.01
- Stochastic Oscillator
- PBYI 35.82
- ENX 30.43
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.